Table Graph
      published meta-analysis   sensitivity analysis   studies

ivermectin in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsNCT04422561 (Shouman), 2020 0.50 [0.01; 25.20] 0.50[0.01; 25.20]NCT04422561 (Shouman), 202010%304NAnot evaluable new illness compatible with Covid-19 detailed resultsIvercar-Tuc, 2021 0.13 [0.04; 0.47] NCT04422561 (Shouman), 2020 0.06 [0.03; 0.11] 0.07[0.03; 0.14]Ivercar-Tuc, 2021, NCT04422561 (Shouman), 2020220%538seriousnot evaluable serious adverse eventsdetailed resultsNCT04422561 (Shouman), 2020 0.50 [0.01; 25.20] 0.50[0.01; 25.20]NCT04422561 (Shouman), 202010%304NAnot evaluable adverse eventsdetailed resultsNCT04422561 (Shouman), 2020 11.52 [0.67; 197.97] 11.52[0.67; 197.97]NCT04422561 (Shouman), 202010%304NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-04-30 12:52 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 684,886 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons